Key Figures

	2021¹	2020¹
Earnings	Mio. Euro	Mio. Euro
Sales revenue	1,7	8,5
Other income	0,6	1,1
Operating expenses	(27,9)	(27,9)
Operating result	(25,6)	(18,3)
Earnings before tax	(26,1)	(18,4)
Net loss for the period	(26,1)	(18,4)
Earnings per share in EUR	(0,80)	(0,61)

Balance sheet as of 30.11.
Total assets	21,7	19,6
Cash and cash equivalents	6,1	5,0
Equity	6,7	12,9
Equity ratio² in %	30,8	65,7

Cash flow
from operating activities	(26,6)	(17,9)
from investing activities	(1,4)	(1,3)
from financing activities	29,1	14,3

Employees
Employees as of 30.11.³	96	84

¹ The reporting period begins on 1 December and ends on 30 November
² Equity / total assets
³ Including members of the Executive Management Board

Outlook

	Guidance 2022 EUR m	rev. guidance 10/22
Sales revenue and other income	7.5 – 9.5	18.5 – 20.5
Operating expenses	41.0 – 45.0	35.0 – 39.0
Operating result (EBIT)	(32.5) – (36.5)	(16.0) – (20.0)
Total funding requirement¹	33.0 – 37.0	8.0 – 11.0
Funds required per month¹	2.8 – 3.1	0.6 – 0.9

¹ Not including any corporate actions

© Heidelberg Pharma AG. All rights reserved.